Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer
- 31 December 1992
- journal article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 47 (3), 282-286
- https://doi.org/10.1016/0090-8258(92)90127-5
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Hexamethylmelamine for the treatment of ovarian cancer—The Mount Sinai experienceCancer Treatment Reviews, 1991
- Hexamethylmelamine (altretamine): Early National Cancer Institute trialsCancer Treatment Reviews, 1991
- Hexamethylmelamine (altretamine) activity as a single agent in previously untreated advanced ovarian cancerCancer Treatment Reviews, 1991
- Hexamethylmelamine as a single second-line agent in ovarian cancerGynecologic Oncology, 1990
- Role of Hexamethylmelamine in the Treatment of Ovarian Cancer: Where is the Needle in the Haystack?JNCI Journal of the National Cancer Institute, 1988
- Hexamethylmelamine in ovarian cancer after failure of cisplatin-based multiple-agent chemotherapyGynecologic Oncology, 1987
- Hexamethylmelamine, methotrexate, 5-fluorouracil as second line chemotherapy after platinum for epithelial ovarian malignanciesGynecologic Oncology, 1986
- Common Epithelial Cancer of the OvaryNew England Journal of Medicine, 1985
- Failure of hexamethylmelamine as salvage therapy in ovarian epithelial adenocarcinoma resistant to combination chemotherapyGynecologic Oncology, 1984
- The role of hexamethylmelamine in advanced ovarian carcinoma treatmentGynecologic Oncology, 1981